Executive Moves | Healthcare | BioTuesdays by Kilmer Lucas IR

Executive Moves

Akcea names Damien Devitt as CEO

Damien Devitt, who has been interim CEO of Akcea Therapeutics (NASDAQ:AKCA) since September 2019, has been promoted to CEO, effective immediately, and will continue to serve as a member of Akcea’s board. “With his...

March 24, 2020

Executive Moves

Covetrus names Benjamin Wolin as CEO

Benjamin Wolin Benjamin Wolin, who has been acting CEO of Covetrus (NASDAQ:CVET) since October 2019, has been promoted to president and CEO, effective immediately. Covetrus was formed in February 2019 as the result of a...

March 4, 2020

Executive Moves

BioSig appoints John Osborn as consultant on autonomic neuromodulation

BioSig Technologies (NASDAQ:BSGM) signed a consulting agreement with John Osborn, Prof. in the Department of Surgery and director of the Minnesota Consortium for Autonomic Neuromodulation at University of Minnesota...

March 4, 2020

Executive Moves

Renowned veterinarian, Dr. Jean Gauvin, joins Kane Biotech as chief veterinary officer

Jean Gauvin Kane Biotech (TSX-V:KNE) appointed renowned Canadian veterinarian, Dr. Jean Gauvin, as its chief veterinary officer. Dr. Gauvin will serve as a liaison between Kane Biotech and industry; guide the company’s...

February 20, 2020

Executive Moves

Verona Pharma announces senior management changes

Verona Pharma (NASDAQ:VRNA) has appointed David Zaccardelli as president, CEO, and director; and Mark Hahn as CFO. Mr. Zaccardelli will replace current CEO, Jan-Anders Karlsson, who is retiring. Mr. Zaccardelli...

February 3, 2020

Executive Moves

ArcherDX names Mark Massaro as CFO

Mark Massaro Closely-held ArcherDX appointed research industry veteran, Mark Massaro, as its CFO. “Mark’s extensive knowledge of the diagnostics landscape, coupled with his more than 20 years of industry...

January 8, 2020

Executive Moves

Indalo appoints healthcare industry veteran Michael Heffernan as board chair

Closely-held Indalo Therapeutics appointed Michael Heffernan as chair of its board of directors. “Indalo’s unique approach to treating fibrosis, combined with a highly experienced team and world-class financial backers...

December 17, 2019

Executive Moves

Zenabis names Kevin Coft as interim CEO

Zenabis Global (TSX:ZENA) appointed Kevin Coft as interim CEO, effective immediately, replacing Andrew Grieve, whose contract was set to expire shortly. While Mr. Grieve will be returning to his investment business, he...

December 11, 2019

Executive Moves

Gerald Solensky resigns as Zomedica CEO; Shameze Rampertab named interim CEO

Gerald Solensky, Jr. has resigned as CEO, chairman and a director of Zomedica Pharmaceuticals (NYSE American, TSXV:ZOM), effective immediately. He will continue as a consultant to the company’s operating...

December 3, 2019

Executive Moves

Zenabis appoints finance expert Vincent Quan as director

Zenabis Global (TSX:ZENA) appointed Vincent Quan as a director of the company, effective immediately. Mr. Quan has more than 17 years of experience in corporate finance, specializing in the North American agriculture...

November 21, 2019

Executive Moves

Liminal BioSciences names Moira Daniels to head regulatory affairs, quality assurance

Liminal BioSciences (TSX:LMNL; OTCQX:LMNL) appointed Moira Daniels as the new head of regulatory affairs and quality assurance based at the company’s offices in Cambridge, UK. “Moira brings many years of global...

November 13, 2019

Executive Moves

Vireo Health names Bruce Linton as executive chairman

Vireo Health International (CNSX:VREO; OTCQX:VREOF) appointed Bruce Linton to the role of executive chairman, where he will serve as a director, work closely with Vireo CEO and founder, Dr. Kyle Kingsley, and spearhead...

November 7, 2019

Executive Moves

Orthofix appoints Jon Serbousek as president and CEO

Jon Serbousek Orthofix Medical (NASDAQ:OFIX) appointed Jon Serbousek as president, CEO and a director of its board, effective immediately. Mr. Serbousek succeeds Brad Mason, who previously announced his retirement. Mr...

November 1, 2019

Executive Moves

Hepion appoints renowned liver disease expert, Dr. Stephen Harrison, as consultant medical director

Stephen Harrison Hepion Pharmaceuticals (NASDAQ:HEPA) appointed world-renowned Dr. Stephen Harrison as consultant medical director. Dr. Harrison is a peer-reviewer for more than 20 medical journals. He is...

October 10, 2019

Executive Moves

Anixa Biosciences names cancer vaccine pioneer, Dr. Ian Frazer to SAB

Ian Frazer Anixa Biosciences (NASDAQ:ANIX) appointed cancer vaccine pioneer, Dr. Ian Frazer, to its scientific advisory board. Dr. Frazer is a leading immunologist recognized as one of the first scientists to...

October 10, 2019

Executive Moves

Zosano Pharma names Steven Lo as CEO

Steven Lo Zosano Pharma (NASDAQ:ZSAN) has appointed Steven Lo as president, CEO and a director, effective Oct. 21. Mr. Lo is departing from his role as CCO at Puma Biotechnology (NASDAQ:PUMA), effective Oct. 18, where...

October 8, 2019

Executive Moves

Canaccord names veteran biotech analyst, Edward Nash, as managing director, equity research

Canaccord Genuity appointed Edward Nash as its New York office’s managing director, equity research. Mr. Nash completes Canaccord Genuity’s team of five senior biotechnology analysts and will focus on companies...

October 7, 2019

Executive Moves

Cerecin names Lilian Chow as VP of clinical operations and regulatory affairs

Lilian Chow Closely-held Cerecin appointed Lilian Chow as VP of clinical operations and regulatory affairs, responsible for leading Cerecin’s upcoming Phase 3 study of tricaprilin for the treatment of Alzheimer’s...

October 7, 2019

Executive Moves

Hepion Pharma promotes Daren Ure, Daniel Trepanier and Patrick Mayo to management team

Hepion Pharmaceuticals (NASDAQ:HEPA) promoted Daren Ure, Daniel Trepanier and Patrick Mayo to the new roles of CSO; SVP of drug development; and SVP of clinical pharmacology, respectively, to further advance the...

October 3, 2019

Executive Moves

Sangamo Therapeutics names Dr. Bettina Cockroft as SVP and CMO

Bettina Cockroft Sangamo Therapeutics (NASDAQ:SGMO) appointed Dr. Bettina Cockroft as SVP and CMO to oversee clinical development activities and operations. Sangamo is using its ex vivo gene-edited cell...

September 30, 2019

Executive Moves

electroCore names Daniel Goldberger as CEO

Daniel Goldberger electroCore (NASDAQ:ECOR) has appointed Daniel Goldberger as CEO, effective Oct. 1. Mr. Goldberger has more than 35 years of experience in the biotechnology and medical technology industries; with...

September 30, 2019

Executive Moves

Catabasis Pharma names Andrew Komjathy as chief commercial officer

Andrew Komjathy Catabasis Pharmaceuticals (NASDAQ:CATB) appointed Andrew Komjathy as its chief commercial officer. Catabasis’ lead program is edasalonexent for the treatment of Duchenne muscular dystrophy (DMD). The...

September 25, 2019

Subscribe